Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

20112,496 citationsJournal Articlegreen Open Access

Authors

José Baselga · Massachusetts General Hospital

Javier Cortés · Vall d'Hebron Institute of Oncology

Sung‐Bae Kim · Asan Medical Center

Seock‐Ah Im · Seoul National University

Roberto Hegg · Hospital Pérola Byington

Young‐Hyuck Im · Sungkyunkwan University

Laslo Roman ·

Abstract

The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).

Topics & Keywords

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 2, pp. 109-119

DOI: 10.1056/nejmoa1113216

Field-Weighted Citation Impact: 98.87